By Tiisetso Motsoeneng and Kaustubh Kulkarni
JOHANNESBURG/MUMBAI (Reuters) - Cipla Ltd has put on hold a $215 million bid for control of South African generic drug firm Cipla Medpro, the chairman of the drug maker said on Monday.
YK Hamied, chairman of the Cipla Ltd, did not give a reason why the drug maker has put on hold its bid for a 51 percent stake in South Africa's third-largest generic drug seller.
Shares in Cipla Medpro fell 4.47 percent to 8.98 rand as of 1102 GMT, still above the 8.55 rand a share Cipla Ltd offered in November last year.
Cipla Medpro said it has not received any word from Hamied that the deal had been put on hold.
"We have not received any communication from Cipla Ltd about its withdrawal from the talks," Johan du Preez, Cipla Medpro's acting CEO, told Reuters.
"As far as we are concerned, the talks are ongoing."
(Editing by David Dolan)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app